News

Video

CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer

Author(s):

Laura Huppert, MD,Yara Abdou, MD

Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 24th 2025 - Apr 25th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Related Content
Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 28th 2025

Bria-IMT Plus Checkpoint Inhibition Is Safe and Yields Clinical Benefit in Pretreated Metastatic Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
April 25th 2025

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Nerea Lopetegui-Lia, MD, breast medical oncologist, assistant professor, The Ohio State University Comprehensive Cancer Center—James
April 21st 2025

Fertility and Toxicity Considerations Factor into TNBC Management

Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 21st 2025

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC